Hope for ALS: phase 3 trial of pridopidine aims to slow disease

NCT ID NCT07322003

First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times

Summary

This phase 3 trial tests if the drug pridopidine can slow the progression of ALS, a serious nerve disease. About 500 adults with ALS will take either pridopidine or a placebo daily for 48 weeks, followed by an open-label period where everyone gets the drug. Researchers will measure changes in physical function and survival to see if the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Genge Partners

    RECRUITING

    Montreal, Quebec, H4P 2N2, Canada

    Contact Email: •••••@•••••

  • Sean M. Healey & AMG Center for ALS

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Somnos Clinical Research

    RECRUITING

    Lincoln, Nebraska, 68506, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • Texas Neurology

    RECRUITING

    Dallas, Texas, 75206, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Kansas

    RECRUITING

    Fairway, Kansas, 66205, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.